Product Launches & Openings

The Corporate Presence has designed commemoratives for launches ranging from software to podcasts to FDA-approved drugs and treatments; and for openings ranging from college buildings to wind farms to Broadway musicals.

Want to see what we can do for your organization?

FDA Clearance Crystal Commemorative

Custom crystal celebrating FDA acceptance of the Investigational Drug Application for XTX101, a potential treatment for cancer patients.

1 Image

FDA Approval Commemorative with Embedded Drug Vial

Custom Lucite, with an embedded drug vial, celebrating FDA approval of Cosela. (20ADH005)

1 Image

Custom Crystal for App Launch

Custom crystal celebrating the launch by fintech firm Bakkt of its digital wallet app.

1 Image

Solar Industry Crystal Deal Toy

Crystal deal toy celebrating the opening by Florida Power & Light of four solar power plants.

2 Images
Financial tombstone marking the opening of four solar power plants by Florida Power & Light.

Venture Capital Firm Founding Commemorative

Custom crystal and wood commemorative celebrating the founding of Uneti Ventures, a venture capital firm focused on finTech, greenTech, and medTech.

2 Images
Custom wood and crystal commemorative celebrating the launch of venture capital firm Uneti Ventures.

Custom Lucite Commemorating Opening Night

Custom Lucite commemorating the opening night on Broadway of the musical “Hadestown”.

2 Images
Custom Lucite commemorative marking the Broadway debut of the musical "Hadestown".

Champagne Cork-Themed Custom Lucite

Custom Lucite, with an embedded champagne cork, celebrating the approval by the Food and Drug Administration (FDA) of the obesity treatment Plenity. Plenity was developed by Boston-based biotech firm Gelesis.

1 Image

New Drug Application Custom Crystal

Custom crystal celebrating the submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA). The application, related to Impel NeuroPharma’s migraine treatment INP104, was supported by a Phase 3, open-label STOP-301 Trial.

2 Images
Crystal commemorative marking the submission to the Food and Drug Administration (FDA) of a New Drug Application (NDA). INP104 was developed for the acute treatment of migraine headaches.